Eye Injections
Showing 1 - 25 of 9,373
Pachychoroid Neovasculopathy Trial (Three monthly injections of intravitreal aflibercept)
Not yet recruiting
- Pachychoroid Neovasculopathy
- Three monthly injections of intravitreal aflibercept
- (no location specified)
Dec 14, 2022
Diabetic Macular Edema, Retinal Disease, Macular Edema Trial in United States (Aflibercept, foselutoclax)
Not yet recruiting
- Diabetic Macular Edema
- +8 more
-
Bakersfield, California
- +7 more
Aug 23, 2023
Intravitreal Injection, Ocular Rinse, Age-Related Macular Degeneration Trial in Oklahoma City (OSDI questionnaire, SPEEDII
Completed
- Intravitreal Injection
- +4 more
- OSDI questionnaire
- SPEEDII questionnaire
-
Oklahoma City, OklahomaDean McGee Eye Institute
Nov 7, 2022
Radiation Retinopathy, Visual Impairment Trial (Faricimab, fluocinolone acetonide)
Not yet recruiting
- Radiation Retinopathy
- Visual Impairment
- Faricimab
- fluocinolone acetonide
- (no location specified)
Apr 25, 2023
Neovascular Age-related Macular Degeneration Trial (Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule,
Not yet recruiting
- Neovascular Age-related Macular Degeneration
- Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule
- Intravitreal injections of 6 mg faricimab on a home optical coherence tomography-guided treatment schedule
- (no location specified)
Jun 6, 2023
Use of Aflibercept Injections Into Eye for Treatment of Eye
Recruiting
- Retinal Disease
- Aflibercept (BAY86-5321, Eylea)
-
Multiple Locations, MexicoMany locations
Aug 22, 2022
Diabetic Macular Edema Trial in Tehran (Injections of 1.25 mg of intravitreal bevacizumab with Timolol and Dorzolamide,
Active, not recruiting
- Diabetic Macular Edema
- Injections of 1.25 mg of intravitreal bevacizumab with Timolol and Dorzolamide
- Injections of 1.25 mg of intravitreal bevacizumab with artificial tears
-
Tehran, Iran, Islamic Republic ofOphthalmic Research Center
Oct 6, 2021
Neovascular Age-related Macular Degeneration, Retinal Disease, Retinal Degeneration Trial in United States (GEM103, sham + SoC)
Completed
- Neovascular Age-related Macular Degeneration
- +3 more
- GEM103
- sham + SoC
-
Phoenix, Arizona
- +22 more
Mar 22, 2022
Non Infectious Uveitis Trial in Worldwide (DE-109 Intravitreal Injections, Sham Procedure)
Recruiting
- Non Infectious Uveitis
- DE-109 Intravitreal Injections
- Sham Procedure
-
Phoenix, Arizona
- +71 more
Nov 4, 2021
Macular Degeneration, Age-Related, Geographic Atrophy Trial in United States (FHTR2163)
Terminated
- Macular Degeneration, Age-Related
- Geographic Atrophy
-
Bakersfield, California
- +51 more
Nov 22, 2022
Endophthalmitis Trial in Toronto (Tap and Inject (TAI), Pars Plana Vitrectomy (PPV))
Recruiting
- Endophthalmitis
- Tap and Inject (TAI)
- Pars Plana Vitrectomy (PPV)
-
Toronto, Ontario, CanadaSt. Michael's Hospital Eye Clinic
Apr 26, 2021
Diabetic Retinopathy Trial in Puerto Rico, United States (Aflibercept Injection)
Recruiting
- Diabetic Retinopathy
- Aflibercept Injection
-
Beverly Hills, California
- +13 more
Jan 6, 2022
Geographic Atrophy Trial in Worldwide (APL-2, Sham Procedure)
Active, not recruiting
- Geographic Atrophy
- APL-2
- Sham Procedure
-
Phoenix, Arizona
- +111 more
Jun 20, 2022
Reading Speed Improvements in Wet-AMD Patients After Ranibizumab
Completed
- Ophthalmopathy
- Wet Macular Degeneration
- (no location specified)
Jul 20, 2021
Proliferative Vitreoretinopathy Trial in United States (ADX-2191 (intravitreal methotrexate 0.8%), Standard surgical care
Recruiting
- Proliferative Vitreoretinopathy
- ADX-2191 (intravitreal methotrexate 0.8%)
- Standard surgical care procedure
-
Phoenix, Arizona
- +22 more
Jan 31, 2022
Geographic Atrophy Trial in Worldwide (APL-2, Sham Procedure)
Active, not recruiting
- Geographic Atrophy
- APL-2
- Sham Procedure
-
Phoenix, Arizona
- +140 more
Jun 20, 2022
Dry Age-related Macular Degeneration, Geographic Atrophy, Macular Degeneration Trial in United States (GEM103)
Terminated
- Dry Age-related Macular Degeneration
- +4 more
-
Phoenix, Arizona
- +28 more
Mar 22, 2022
Neovascular Age-Related Macular Degeneration Trial in United States (PDS Implant filled with 100 mg/mL Ranibizumab, Intravitreal
Completed
- Neovascular Age-Related Macular Degeneration
- PDS Implant filled with 100 mg/mL Ranibizumab
- Intravitreal Injections of 10 mg/mL Ranibizumab
-
Mesa, Arizona
- +76 more
Feb 28, 2022
Diabetes, Diabetic Retinopathy, Diabetic Macular Edema Trial in Worldwide (THR-687 dose level 1, THR-687 dose level 2, THR-687
Terminated
- Diabetes Mellitus
- +2 more
- THR-687 dose level 1
- +3 more
-
Huntington Beach, California
- +24 more
Jul 19, 2022
Age-Related Macular Degeneration Trial in Philippines, United States (2.0 mg DE-122 Injectable Solution + Lucentis, 4.0 mg
Completed
- Age-Related Macular Degeneration
- 2.0 mg DE-122 Injectable Solution + Lucentis
- +2 more
-
Gilbert, Arizona
- +13 more
Jun 22, 2021
Pathologic Myopia Trial in Lutsk, Mykolaiv, Odesa (Intravitreal injection)
Recruiting
- Pathologic Myopia
- Intravitreal injection
-
Lutsk, Ukraine
- +3 more
Mar 23, 2022
Dry Eye Disease in Stavanger: Dry Eye Disease in Patients
Enrolling by invitation
- Dry Eye
- Oculus Keratograph. Schirmer test. Tear fluid sample.
-
Stavanger, NorwayStavanger University Hospital, Department of Ophthalmology
Jul 2, 2020
Diabetes, Diabetic Retinopathy, Diabetic Macular Edema Trial in Worldwide (THR-149 dose level 1, THR-149 dose level 2, THR-149
Recruiting
- Diabetes Mellitus
- +2 more
- THR-149 dose level 1
- +6 more
-
Beverly Hills, California
- +60 more
Aug 9, 2022